Abstract
IntroductionInterventional clinical trials in recurrent miscarriage use varying expected effect sizes to inform their sample size calculations. Often these are not informed by what stakeholders consider a meaningful treatment effect. Adaptive trial designs may integrate stakeholder views on trial success and futility but the criteria to inform this is lacking. This study aims to understand relevant stakeholder views of what is considered a worthwhile treatment effect for miscarriage prevention interventions and what is acceptable stopping criteria in miscarriage clinical trials.Methods and analysisThe study is designed as a cross-sectional online anonymous survey. The survey presents different scenarios to respondents relating to varying target differences and probability thresholds and explores success and futility criteria for clinical trials. The survey was developed with personal and public involvement (PPI) through focus groups and a PPI partner. Eligible participants will be those with a personal history of miscarriage, including partners, and healthcare professionals who manage patients who experience a miscarriage. Convenience, snowball and purposive sampling techniques will be employed to invite eligible participants to complete the survey. The survey will be accepting responses for an initial 2-week pilot to check validity, prior to being open for a further 12 weeks. Descriptive analyses and linear regression analyses will synthesise the survey results.Ethics and disseminationEthical approval was obtained from the NHS Research Ethics Committee North West—Greater Manchester East (23/NW/0322) on 30 January 2024. Informed consent will be obtained prior to survey completion. No personal identifying information will be collected. The results will be published in a relevant scientific journal and communicated through our institutional website.
Funder
Efficacy and Mechanism Evaluation Programme
Medical Research Council
Reference19 articles.
1. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss;Quenby;Lancet,2021
2. Genetic causes of sporadic and recurrent miscarriage;Melo;Fertil Steril,2023
3. Recurrent miscarriage: evidence to accelerate action;Coomarasamy;Lancet,2021
4. Unexplained recurrent pregnancy loss: novel causes and advanced treatment;Yu;J Reprod Immunol,2023
5. Chow S-C , Shao J , Wang H , et al . Sample size calculations in clinical. 3rd edn. CRC press, 2017. Available: https://www.taylorfrancis.com/books/9781351727129